» Articles » PMID: 19684043

A Double-blind, Non-inferiority RCT Comparing Corifollitropin Alfa and Recombinant FSH During the First Seven Days of Ovarian Stimulation Using a GnRH Antagonist Protocol

Overview
Journal Hum Reprod
Date 2009 Aug 18
PMID 19684043
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Corifollitropin alfa, a fusion protein lacking LH activity, has a longer elimination half-life and extended time to peak levels than recombinant FSH (rFSH). A single injection of corifollitropin alfa may replace seven daily gonadotrophin injections during the first week of ovarian stimulation.

Methods: In this large, double-blind, randomized, non-inferiority trial the ongoing pregnancy rates were assessed after one injection of 150 microg corifollitropin alfa during the first week of stimulation and compared with daily injections of 200 IU rFSH using a standard GnRH antagonist protocol.

Results: The study population comprised 1506 treated patients with mean age of 31.5 years and body weight of 68.6 kg. Ongoing pregnancy rates of 38.9% for the corifollitropin alfa group and 38.1% for rFSH were achieved, with an estimated non-significant difference of 0.9% [95% confidence interval (CI): -3.9; 5.7] in favor of corifollitropin alfa. Stratified analyses of pregnancy rates confirmed robustness of this primary outcome by showing similar results regardless of IVF or ICSI, or number of embryos transferred. A slightly higher follicular response with corifollitropin alfa resulted in a higher number of cumulus-oocyte-complexes compared with rFSH [estimated difference 1.2 (95% CI: 0.5; 1.9)], whereas median duration of stimulation was equal (9 days) and incidence of (moderate/severe) ovarian hyperstimulation syndrome was the same (4.1 and 2.7%, respectively P = 0.15).

Conclusion: Corifollitropin alfa is a novel and effective treatment option for potential normal responder patients undergoing ovarian stimulation with GnRH antagonist co-treatment for IVF resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. The trial was registered under ClinicalTrials.gov identifier NTC00696800.

Citing Articles

The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.

Wu L, Yin H, Guan L, Li G, Zhang J, Shen Q Sci Rep. 2025; 15(1):2666.

PMID: 39837901 PMC: 11751185. DOI: 10.1038/s41598-025-86962-4.


Development of a Long-Acting Follicle-Stimulating Hormone Using Serum Albumin Fab-Associated Technology for Female Infertility.

Kim D, Cho Y, Kang M, Lee S, Lee S, Yun B Endocrinol Metab (Seoul). 2024; 40(1):146-155.

PMID: 39628267 PMC: 11898319. DOI: 10.3803/EnM.2024.2090.


Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial.

Alvarado Franco C, Bernabeu Garcia A, Sunol Sala J, Guerrero Villena J, Albero Amoros S, Llacer J Front Reprod Health. 2023; 5:1239175.

PMID: 37965590 PMC: 10642283. DOI: 10.3389/frph.2023.1239175.


Exploring the Impact of Controlled Ovarian Stimulation and Non-Invasive Oocyte Assessment in ART Treatments.

Sciorio R, Cariati F, Fleming S, Alviggi C Life (Basel). 2023; 13(10).

PMID: 37895371 PMC: 10608727. DOI: 10.3390/life13101989.


Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis.

Sparaco M, Carbone L, Landi D, Ingrasciotta Y, Di Girolamo R, Vitturi G CNS Drugs. 2023; 37(10):849-866.

PMID: 37679579 PMC: 10570169. DOI: 10.1007/s40263-023-01036-1.


References
1.
Tarlatzis B, Fauser B, Kolibianakis E, Diedrich K, Rombauts L, Devroey P . GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006; 12(4):333-40. DOI: 10.1093/humupd/dml001. View

2.
Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J . Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2004; 19(9):1979-84. DOI: 10.1093/humrep/deh369. View

3.
Boivin J, Takefman J . Impact of the in-vitro fertilization process on emotional, physical and relational variables. Hum Reprod. 1996; 11(4):903-7. DOI: 10.1093/oxfordjournals.humrep.a019276. View

4.
Schroder A, Katalinic A, Diedrich K, Ludwig M . Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reprod Biomed Online. 2004; 8(5):600-6. DOI: 10.1016/s1472-6483(10)61110-8. View

5.
Verwoerd G, Mathews T, Brinsden P . Optimal follicle and oocyte numbers for cryopreservation of all embryos in IVF cycles at risk of OHSS. Reprod Biomed Online. 2008; 17(3):312-7. DOI: 10.1016/s1472-6483(10)60213-1. View